Information Provided By:
Fly News Breaks for August 10, 2018
MDT, EW
Aug 10, 2018 | 08:57 EDT
SunTrust analyst Bruce Nudell lowered his price target on Edwards Lifesciences to $170 citing increased Transcatheter aortic valve replacement, or TAVR, competition. The analyst keeps his Buy rating on the shareshowever, expecting the company to show increased TAVR momentum in the U.S. in Q4 thanks to the "Partner 3 CAP program and the Centera U.S. IDE which will likely cannibalize CoreValve".
News For EW;MDT From the Last 2 Days
There are no results for your query EW;MDT